Ikena Oncology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, reporting beneficial ownership of 959,337 shares of ImageneBio, Inc. common stock, representing 8.51% of the class.
Trails Edge Capital Partners and affiliates have reported a 9.9% beneficial ownership stake in ImageneBio, Inc. through common stock and pre-funded warrants.
Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in IMAGENEBIO, Inc. common stock.
Blue Owl Capital Holdings LP has reported a 7.37% beneficial ownership stake in ImageneBio, Inc., holding 823,785 shares of common stock.
Funicular Funds, LP, along with Cable Car Capital, LP and Jacob Ma-Weaver, reported a passive beneficial ownership of 5.8% in ImageneBio, Inc. common stock.
Biotechnology Value Fund L.P. and its affiliates reported a 7.2% beneficial ownership stake in ImageneBio, Inc. common stock as of September 30, 2025.
Blue Owl Capital Holdings LP has reported a 4.84% passive beneficial ownership stake in ImageneBio, Inc. as of September 30, 2025.
Deep Track Capital, along with its affiliates, has disclosed a beneficial ownership of 7.86% in ImageneBio, Inc.'s common stock.
Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in Ikena Oncology, Inc.
Deep Track Capital, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a collective beneficial ownership of 5.21% of Ikena Oncology, Inc.'s common stock.
Biotechnology Value Fund and its affiliated entities, including Mark N. Lampert, have disclosed an updated aggregate beneficial ownership of 8.3% of Ikena Oncology, Inc.'s common stock as of December 31, 2024.
SCHEDULE 13G/A: BML Investment Partners and Braden M. Leonard Disclose Significant 7.6% Stake in Ikena Oncology
BML Investment Partners, L.P. and Braden M. Leonard have disclosed a combined beneficial ownership of 7.6% of Ikena Oncology, Inc.'s common stock as of December 31, 2024.
SCHEDULE 13G/A: Gilead Sciences Discloses 3.6% Stake in Ikena Oncology
Gilead Sciences, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 3.6% of Ikena Oncology, Inc.'s common stock as of December 31, 2024.